News & Updates

Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

08/05/2021

Excerpt from the Press Release: MONMOUTH JUNCTION, N.J., July 15, 2021 (GLOBE NEWSWIRE) — Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the initiation of its Phase 1 clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer. The study, being conducted at…

Read More

Pear Therapeutics Reports Nine-Month Real-World Healthcare Utilization Data for reSET-O®

08/04/2021

Excerpt from the Press Release: BOSTON & SAN FRANCISCO–(BUSINESS WIRE)–Pear Therapeutics, Inc. today announced results from an extended retrospective analysis of real-world data analyzing healthcare resource utilization for reSET-O®, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD). Results from a nine-month real-world data analysis show a continued…

Read More

CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity

08/04/2021

Excerpt from the Press Release: MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced an update on the timing for the release of the data for its Phase 1a/1b clinical study of…

Read More

ORYZON receives approval to start EVOLUTION Phase IIb trial with vafidemstat in schizophrenia

08/04/2021

Excerpt from the Press Release: MADRID, Spain and CAMBRIDGE, Mass., July 13, 2021 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it has received approval from the Spanish Drug Agency (AEMPS) for its Clinical…

Read More

Artax Biopharma Granted MHRA Clinical Trial Authorization for AX-158

08/03/2021

Excerpt from the Press Release: CAMBRIDGE, Mass., July 13, 2021 /PRNewswire/ — Artax Biopharma, Inc., a biotechnology company focused on transforming the treatment of T Cell-mediated diseases, today announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted clinical trial authorization to evaluate AX-158 in a Phase 1 clinical trial for the treatment of T Cell-Mediated Diseases.…

Read More

Echocardiography Can Determine Mortality Risk in COVID-19 Patients

08/03/2021

Excerpt from the Press Release: Echocardiography parameters and ARDS linked to higher mortality risk for hospitalized patients. Transthoracic echocardiography (TTE) plays a role in pinpointing the risk a COVID-19-positive patient has of dying. In a study published July 21 in the European Journal of Clinical Investigation, a team of investigators from Italy determined that left ventricular ejection…

Read More

Immunicom’s Data at ASCO Expand on the Antitumor Activity of its Novel Non-Pharmaceutical Immunotherapy in Late-Stage Breast Cancer Patients

08/03/2021

Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Immunicom, Inc., a clinical stage biotech, shared preliminary data from its metastatic triple-negative breast cancer (mTNBC) clinical trial with its novel breakthrough Immunopheresis® therapy at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021. Immunicom’s subtractive immunotherapies are designed to remove immune inhibitors and enhance patients natural immune…

Read More

Q-State Biosciences Awarded NIH Grant for the Development of ASO Therapies Targeting Cancer Pain

08/02/2021

Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Q-State Biosciences (“Q-State”), a discovery technology and therapeutics company advancing programs for the treatment of epilepsy, pain, and other disorders of the central nervous system,today announced it has been awarded a non-dilutive grant of $1.3 million from the National Cancer Institute (NCI) of the National Institutes of Health (NIH)…

Read More

Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

08/02/2021

Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Magenta Therapeutics, Inc. (Nasdaq: MGTA) today announced that it has received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) filed in June 2021 to initiate a Phase 1/2 clinical trial of MGTA-117 in patients with acute…

Read More

IM Therapeutics Reports Positive Results in Safety, Tolerability and Mechanism of Action of Phase 1b Trial of Lead Drug IMT-002 in Type 1 Diabetes

08/02/2021

Excerpt from the Press Release: WOBURN, Mass.–(BUSINESS WIRE)–IM Therapeutics, a clinical-stage company developing first-in-class human leukocyte antigen (HLA)-targeted therapies to treat autoimmune diseases, today announced positive results on safety, tolerability, pharmacokinetics (PK) and mechanistic action in a Phase 1b study of IMT-002 in patients with type 1 diabetes (T1D). The study, a first for the…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives